Cargando…
High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins
Chemical probes are important tools for understanding biological systems. However, because of the huge combinatorial space of targets and potential compounds, traditional chemical screens cannot be applied systematically to find probes for all possible druggable targets. Here, we demonstrate a novel...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864444/ https://www.ncbi.nlm.nih.gov/pubmed/35194925 http://dx.doi.org/10.15252/msb.202110767 |
_version_ | 1784655463144488960 |
---|---|
author | Holbrook‐Smith, Duncan Durot, Stephan Sauer, Uwe |
author_facet | Holbrook‐Smith, Duncan Durot, Stephan Sauer, Uwe |
author_sort | Holbrook‐Smith, Duncan |
collection | PubMed |
description | Chemical probes are important tools for understanding biological systems. However, because of the huge combinatorial space of targets and potential compounds, traditional chemical screens cannot be applied systematically to find probes for all possible druggable targets. Here, we demonstrate a novel concept for overcoming this challenge by leveraging high‐throughput metabolomics and overexpression to predict drug–target interactions. The metabolome profiles of yeast treated with 1,280 compounds from a chemical library were collected and compared with those of inducible yeast membrane protein overexpression strains. By matching metabolome profiles, we predicted which small molecules targeted which signaling systems and recovered known interactions. Drug–target predictions were generated across the 86 genes studied, including for difficult to study membrane proteins. A subset of those predictions were tested and validated, including the novel targeting of GPR1 signaling by ibuprofen. These results demonstrate the feasibility of predicting drug–target relationships for eukaryotic proteins using high‐throughput metabolomics. |
format | Online Article Text |
id | pubmed-8864444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88644442022-03-04 High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins Holbrook‐Smith, Duncan Durot, Stephan Sauer, Uwe Mol Syst Biol Articles Chemical probes are important tools for understanding biological systems. However, because of the huge combinatorial space of targets and potential compounds, traditional chemical screens cannot be applied systematically to find probes for all possible druggable targets. Here, we demonstrate a novel concept for overcoming this challenge by leveraging high‐throughput metabolomics and overexpression to predict drug–target interactions. The metabolome profiles of yeast treated with 1,280 compounds from a chemical library were collected and compared with those of inducible yeast membrane protein overexpression strains. By matching metabolome profiles, we predicted which small molecules targeted which signaling systems and recovered known interactions. Drug–target predictions were generated across the 86 genes studied, including for difficult to study membrane proteins. A subset of those predictions were tested and validated, including the novel targeting of GPR1 signaling by ibuprofen. These results demonstrate the feasibility of predicting drug–target relationships for eukaryotic proteins using high‐throughput metabolomics. John Wiley and Sons Inc. 2022-02-23 /pmc/articles/PMC8864444/ /pubmed/35194925 http://dx.doi.org/10.15252/msb.202110767 Text en © 2022 The Authors. Published under the terms of the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Holbrook‐Smith, Duncan Durot, Stephan Sauer, Uwe High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins |
title | High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins |
title_full | High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins |
title_fullStr | High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins |
title_full_unstemmed | High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins |
title_short | High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins |
title_sort | high‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864444/ https://www.ncbi.nlm.nih.gov/pubmed/35194925 http://dx.doi.org/10.15252/msb.202110767 |
work_keys_str_mv | AT holbrooksmithduncan highthroughputmetabolomicspredictsdrugtargetrelationshipsforeukaryoticproteins AT durotstephan highthroughputmetabolomicspredictsdrugtargetrelationshipsforeukaryoticproteins AT saueruwe highthroughputmetabolomicspredictsdrugtargetrelationshipsforeukaryoticproteins |